Low-dose oral or non-oral hormone therapy: effects on C-reactive protein and atrial natriuretic peptide in menopause

What Was Tested

The paper reports a study of ANP (Atrial Natriuretic Peptide), published as a randomized controlled trial.

Who Took Part

According to the abstract, 44 women were involved.

The age groups tagged for this paper are middle-aged adults, women only.

After 3 months, patients were crossed over without washout.

How the Study Was Run

In design terms this was a randomized and crossover study.

Random assignment meant chance, not the researchers, decided who got ANP (Atrial Natriuretic Peptide) and who got the comparison, which limits bias.

Each person switched between ANP (Atrial Natriuretic Peptide) and the comparison at some point, usually with a gap in between.

The methods mention a period of 3 months.

Post-HT vs. pre-HT measures were determined: lipids, glucose, body mass index, waist circumference, fibrinogen, CRP-stratified levels, and ANP levels.

The study was registered at clinical trials.gov (NCT01432028).

What Was Measured

The subject headings attached to it are Administration, Cutaneous, Androstenes, Atrial Natriuretic Factor, C-Reactive Protein, Cardiovascular Diseases, Drug Combinations and Estradiol.

Author keywords: ATRIAL NATRIURETIC PEPTIDE, CARDIOVASCULAR RISK, HORMONE THERAPY, MENOPAUSE and RANDOMIZED CLINICAL TRIAL.

What This Means in Plain Language

The paper is a randomized and crossover study of ANP (Atrial Natriuretic Peptide) in 44 women over 3 months.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2015 (Climacteric : the journal of the International Menopause Society), a journal based in England.

More context: the ANP (Atrial Natriuretic Peptide) compound page, all human trials.